IshikawaPrefectural Central Hospital

Japan

IshikawaPrefectural Central Hospital

Japan

Time filter

Source Type

Ishiyama Y.,IshikawaPrefectural Central Hospital | Kotake M.,IshikawaPrefectural Central Hospital | Matsunaga M.,IshikawaPrefectural Central Hospital | Kitamura H.,IshikawaPrefectural Central Hospital | And 5 more authors.
Japanese Journal of Cancer and Chemotherapy | Year: 2012

Case 1 was a 58-year-old woman diagnosed with unresectable liver metastases from advanced rectal cancer. We performed laparoscopic low anterior resection for sigmoid cancer. As the first-line treatment, FOLFOX+bevacizumab (BV) was applied for 16 courses. The second-line treatment, FOLFIRI plus BV, was applied for four courses. However, the disease progressed with worsening liver metastases. The sequencing of K-RAS genes from the biopsy specimens of sigmoid colon cancer revealed an expression of a wild-type K-RAS. As the third-line treatment, panitumumab was applied. After 8 courses of this chemotherapy regimen, a significant reduction in the size of liver metastases was observed. Case 2 was an 81-year-old man diagnosed with unresectable liver metastases from advanced rectal cancer. We obliged the patient by performing laparoscopic rectal resection. As the first-line treatment, XELOX plus BV was applied for 10 courses. As the second-line treatment, IRIS was applied for 6 courses. However, this failed to prevent him from having a progressive disease. As the third-line treatment, panitumumab was applied for 2 courses, and a significant reduction in the size of liver metastases was observed. Our findings suggested that panitumumab has great potential for effective treatment of patients with unresectable stage IV colorectal cancer.

Loading IshikawaPrefectural Central Hospital collaborators
Loading IshikawaPrefectural Central Hospital collaborators